Filing Details
- Accession Number:
- 0000899243-21-031361
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-03 18:39:33
- Reporting Period:
- 2020-03-24
- Accepted Time:
- 2021-08-03 18:39:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492674 | T2 Biosystems Inc. | TTOO | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1359316 | M Adrian Jones | C/O Goldman Sachs &Amp; Co. Llc 200 West Street New York NY 10282 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-03-24 | 500 | $0.38 | 4,196,956 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-03-24 | 500 | $0.38 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-03-25 | 600 | $0.93 | 4,197,056 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-03-25 | 600 | $0.93 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-04-09 | 1,000 | $0.49 | 4,197,456 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-04-09 | 1,000 | $0.49 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 2,655 | $0.52 | 4,193,801 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 1,000 | $0.52 | 4,192,801 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 1,000 | $0.53 | 4,191,801 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 500 | $0.53 | 4,191,301 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 50 | $0.53 | 4,191,251 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 500 | $0.53 | 4,190,751 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 100 | $0.53 | 4,190,651 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 6,256 | $0.54 | 4,184,395 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 100 | $0.55 | 4,184,295 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 939 | $0.55 | 4,183,356 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-05-06 | 26,200 | $0.55 | 4,209,556 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 10,100 | $0.57 | 4,199,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 2,000 | $0.57 | 4,197,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-06 | 1,000 | $0.57 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-05-12 | 2,500 | $0.55 | 4,198,956 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-12 | 2,500 | $0.55 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 200 | $0.83 | 4,196,256 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 3,235 | $0.83 | 4,193,021 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 2,031 | $0.83 | 4,190,990 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 2,031 | $0.83 | 4,188,959 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-05-19 | 10,328 | $0.83 | 4,199,287 | No | 4 | P | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 800 | $0.83 | 4,198,487 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2020-05-19 | 2,031 | $0.83 | 4,196,456 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Acquisiton | 2020-05-20 | 5,126 | $0.80 | 4,201,582 | No | 4 | P | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | P | Indirect | See Footnotes |
Footnotes
- These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
- Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
- The Reporting Person is a managing director of Goldman Sachs. Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group").
- GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
- The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Billionaire Hedge Funds
